Last reviewed · How we verify
NCT03728777
Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders
NA trial testing Resveratrol in Mitochondrial Myopathies in 20 participants. Completed in 1 October 2019.
1 October 2019
Quick facts
| Lead sponsor | Rigshospitalet, Denmark |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 9 April 2018 |
| Primary completion | 1 October 2019 |
| Estimated completion | 1 October 2019 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Resveratrol — full drug profile →
Conditions studied
- Mitochondrial Myopathies — all drugs for Mitochondrial Myopathies →
- Fatty Acid Oxidation Defects — all drugs for Fatty Acid Oxidation Defects →
Sponsor
Rigshospitalet, Denmark
Who can join
Adults 18 to 80, any sex, with Mitochondrial Myopathies or Fatty Acid Oxidation Defects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate the potential beneficial effects of a daily supplement of Resveratrol (1000mg/day) on physical ability and on muscle metabolism in patients with verified mitochondrial myopathy and patients with a verified fatty acid oxidation defect of VLCAD and CPTII deficiencies. Investigators hypothesize an improved muscle metabolism, mitochondrial function, fatty acid oxidation and thus improvement of physical ability.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mitochondrial dysfunction: mechanisms and advances in therapy.
Zong Y, Li H, Liao P, Chen L, et al · · 2024 · cited 614× · PMID 38744846 · DOI 10.1038/s41392-024-01839-8 -
The mitophagy pathway and its implications in human diseases.
Wang S, Long H, Hou L, Feng B, et al · · 2023 · cited 484× · PMID 37582956 · DOI 10.1038/s41392-023-01503-7 -
Pharmacological advances in mitochondrial therapy.
Singh A, Faccenda D, Campanella M. · · 2021 · cited 88× · PMID 33647769 · DOI 10.1016/j.ebiom.2021.103244 -
Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities.
Brown K, Theofanous D, Britton RG, Aburido G, et al · · 2024 · cited 80× · PMID 38255828 · DOI 10.3390/ijms25020747 -
Current and Emerging Clinical Treatment in Mitochondrial Disease.
Tinker RJ, Lim AZ, Stefanetti RJ, McFarland R. · · 2021 · cited 64× · PMID 33646563 · DOI 10.1007/s40291-020-00510-6 -
Clinical trials in mitochondrial disorders, an update.
Almannai M, El-Hattab AW, Ali M, Soler-Alfonso C, et al · · 2020 · cited 56× · PMID 33129691 · DOI 10.1016/j.ymgme.2020.10.002 -
Moving towards clinical trials for mitochondrial diseases.
Pitceathly RDS, Keshavan N, Rahman J, Rahman S. · · 2021 · cited 52× · PMID 32618366 · DOI 10.1002/jimd.12281 -
PGC1s and Beyond: Disentangling the Complex Regulation of Mitochondrial and Cellular Metabolism.
Coppi L, Ligorio S, Mitro N, Caruso D, et al · · 2021 · cited 31× · PMID 34199142 · DOI 10.3390/ijms22136913
Verify or expand the search:
- PubMed search for NCT03728777
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Resveratrol
Trials testing the same drug.
- NCT06250283 — Resveratrol for the Prevention of Bone Loss in Postmenopausal Women · NA · completed
- NCT05808387 — The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers · NA · recruiting
- NCT06131918 — Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy · Phase 2 · completed
- NCT05653895 — Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS · NA · completed
- NCT05410093 — Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency · NA · unknown
Other recruiting trials for Mitochondrial Myopathies
Currently open trials in the same condition.
- NCT06754098 — Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency · Phase 2 · recruiting
- NCT05962333 — Effect and Safety MABs Administration m.3243A>G Mutation Carriers · Phase 2 · recruiting
- NCT04086329 — Validation of Oxygen Nanosensor in Mitochondrial Myopathy · Phase 1 · recruiting
- NCT05199740 — mtDNA Mutation Load Analysis in Mesoangioblasts · recruiting
Other Rigshospitalet, Denmark trials
Trials by the same sponsor.
- NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
- NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
- NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
- NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
- NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03728777 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
- Last refreshed: 27 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03728777.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing